Literature DB >> 26325210

Different Surgical Approaches for Spinal Schwannoma: A Single Surgeon's Experience with 49 Consecutive Cases.

Soo Eon Lee1, Tae-Ahn Jahng2, Hyun Jib Kim3.   

Abstract

OBJECTIVE: Comparing different surgical approaches for spinal schwannoma, the safety and efficacy of the minimally invasive surgery (MIS) approach were demonstrated, and a suitable indication for each surgical approach was analyzed.
METHODS: This study comprised 49 consecutive patients with intradural extramedullary schwannoma who underwent surgical resection: 31 patients via MIS approach (MIS group; 6 patients via a muscle-splitting approach using a tubular retractor and 25 patients via unilateral hemilaminectomy preserving the contralateral paraspinal muscle) and 18 patients via total laminectomy (TL group). Medical records including perioperative data and radiologic data were reviewed.
RESULTS: On initial magnetic resonance imaging, the mean maximal sagittal diameter of the tumor was 23.9 mm in the MIS group and 26.9 mm in the TL group, and the mean maximal axial diameter was 16.1 mm in the MIS group and 22.8 mm in the TL group (P = 0.452 and P = 0.011, respectively). The foraminal extension of tumor was identified in 8 patients in the MIS group and 9 patients in the TL group (P = 0.081). The tumor location was the lumbar spine in 20 patients in the MIS group and the cervicothoracic spine in 17 patients in the TL group (P = 0.001). Intraoperatively, all tumors in the MIS group could be totally resected with reduced operative time and blood loss. During the follow-up period of 38.2 months in the MIS group and 51.2 months in the TL group, the clinical improvement was not different between the surgical approaches (P = 0.332).
CONCLUSIONS: Safe and complete resection of intradural extramedullary schwannoma was obtained through the MIS approach. Regardless of sagittal extension of the tumor, a schwannoma with an axial diameter of 16 mm located in the lumbar spine can be effectively treated with the MIS approach, including foraminal extension.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hemilaminectomy; Minimally invasive surgery; Spinal schwannoma; Tubular retractor

Mesh:

Year:  2015        PMID: 26325210     DOI: 10.1016/j.wneu.2015.08.027

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

1.  An Analysis of Clinical Efficacy of Microsurgical Resection of Intradural Neoplasm by Unilateral Approach with Caspar Retractors.

Authors:  Xuan Wang; Hong-Yang Zhao; De-Qiang Lei; Wen-De Zhu; Ying-Chun Zhou
Journal:  Med Princ Pract       Date:  2019-09-20       Impact factor: 1.927

2.  Surgical management of solitary nerve sheath tumors originating around the epiconus or conus medullaris: a retrospective case analysis based on neurological function.

Authors:  Kentaro Naito; Toru Yamagata; Atsufumi Nagahama; Shinichi Kawahara; Kenji Ohata; Toshihiro Takami
Journal:  Neurosurg Rev       Date:  2017-04-03       Impact factor: 3.042

3.  The Optimal Surgical Approach to Intradural Spinal Tumors: Laminectomy or Hemilaminectomy?

Authors:  Amir Goodarzi; Jared Clouse; Tatiana Capizzano; Kee D Kim; Ripul Panchal
Journal:  Cureus       Date:  2020-02-23

4.  [Surgical treatment of intradural extramedullary lesions by hemilaminectomy].

Authors:  Juan F Villalonga; Andrés Cervio
Journal:  Surg Neurol Int       Date:  2017-10-24

5.  Hemorrhagic Spinal Schwannoma in Thoracolumbar Area with Total Paraplegia.

Authors:  Ahmad Jabir Rahyussalim; Rizky Priambodo Wisnubaroto; Tri Kurniawati; Alfariq Senja Belantara Latsarizul; Nuryati Chairani
Journal:  Case Rep Med       Date:  2019-01-02

6.  A Novel Technique of Mixed Reality Systems in the Treatment of Spinal Cord Tumors.

Authors:  Ryoma Aoyama; Ukei Anazawa; Hiraku Hotta; Itsuo Watanabe; Yuichiro Takahashi; Shogo Matsumoto
Journal:  Cureus       Date:  2022-03-12

7.  Non-Syndromic Spinal Schwannomas: A Novel Classification.

Authors:  Ibrahim Sun; M Necmettin Pamir
Journal:  Front Neurol       Date:  2017-07-17       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.